Diabetes education program for Arab Americans
Official title: Project Dulce for Arab Americans With Type 2 Diabetes
Run by Scripps Whittier Diabetes Institute · NCT05580536 · Data updated 2026-11-12
This study tests a diabetes education program designed for Arab Americans to see if it helps them better manage their diabetes and improve their health.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 48 (estimated) |
| Sponsor | Scripps Whittier Diabetes Institute Academic / other |
| Locations | 2 sites (El Cajon, California and 1 other locations) |
| Status | Recruiting |
| Started | February 17, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | March 17, 2026 |
| Trial ID | NCT05580536 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are self-identified Arab Americans diagnosed with type 2 diabetes who meet specific health criteria.
✕Probably not a fit
Patients who are pregnant or currently participating in another diabetes-related study may not receive benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This program, Project Dulce Arabic, aims to improve diabetes self-management among Arab Americans by providing culturally and linguistically appropriate education. It includes a 5-week peer-led educational course in Arabic and a 3-month text messaging support system. The study seeks to enhance participants' diabetes knowledge, beliefs, and self-management behaviors, while also measuring improvements in hemoglobin A1C levels. Additionally, it incorporates genetic education to raise awareness about the genetic factors influencing type 2 diabetes in this community.
Why it matters
Potential benefit: If successful, this program could significantly improve diabetes management and health outcomes for Arab Americans with type 2 diabetes.
How similar studies have gone: Other studies have shown success with culturally tailored diabetes education programs, indicating a promising approach for this population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Are a participant of Metro Caring * Self-identified Arab * Diagnosed with type 2 diabetes mellitus (T2DM) * HbA1c ≥7.5% in the last 30 days * Able to speak, read, write, and comprehend in English and Arabic * Have access to a cell phone that can receive/send text messages throughout the study Exclusion Criteria: * Pregnant * Are currently participating in another diabetes-related study
Where it's running
-
Metro Caring
Denver, Colorado, United States Recruiting -
San Ysidro Health
El Cajon, California, United States Completed
Study contacts
- Principal investigator: Ahmed Khattab, MD — Scripps
- Study coordinator: Ahmed Khattab, MD
- Email: akhattab@scripps.edu
- Phone: 8586782129
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proliverenol for liver fat and insulin resistance in type 2 diabetes
This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes
This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.
-
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes
This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin
This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.